Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

About Collegium Pharmaceutical

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: COLL
  • CUSIP:
Key Metrics:
  • Previous Close: $15.82
  • 50 Day Moving Average: $10.79
  • 200 Day Moving Average: $14.44
  • 52-Week Range: $8.24 - $30.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.29
  • P/E Growth: 0.00
  • Market Cap: $372.21M
  • Outstanding Shares: 23,528,000
  • Beta: 0.2
Profitability:
  • Return on Equity: -59.21%
  • Return on Assets: -51.26%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 6.40%
  • Quick Ratio: 6.33%
Additional Links:
Companies Related to Collegium Pharmaceutical:

Analyst Ratings

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.60 (74.46% upside)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016Jefferies GroupReiterated RatingBuyView Rating Details
9/14/2016Needham & Company LLCReiterated RatingBuy$30.00View Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00View Rating Details
8/11/2016Piper Jaffray Cos.Set Price TargetBuy$27.00 -> $23.00View Rating Details
3/15/2016Janney Montgomery ScottInitiated CoverageBuy$25.00View Rating Details
2/19/2016William BlairInitiated CoverageOutperform$35.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/10/2016Q2($0.76)($1.05)ViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.29)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
Current Year EPS Consensus Estimate: $-3.86 EPS
Next Year EPS Consensus Estimate: $-2.99 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.60)($0.42)($0.51)
Q2 20162($0.74)($0.45)($0.60)
Q3 20162($1.12)($0.85)($0.99)
Q4 20162($1.17)($0.86)($1.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Ownership Percentage: 37.93%
Institutional Ownership Percentage: 62.13%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.25View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
DateHeadline
News IconAllergy Treatment Market 10-Year Market Forecast and Trends Analysis Research Report (NASDAQ:COLL)
www.emailwire.com - September 23 at 9:27 AM
fxpips.com logoThese (Active) Stocks Are Gaining at the Close (NASDAQ:COLL)
www.fxpips.com - September 23 at 9:27 AM
finance.yahoo.com logoCollegium Pharmaceutical (COLL) Jumps: Stock Soars 8.4% (NASDAQ:COLL)
finance.yahoo.com - September 22 at 9:56 AM
News IconStock Perspective: Collegium Pharmaceutical Inc (NASDAQ:COLL) Earnings in View - Frisco Fastball (NASDAQ:COLL)
friscofastball.com - September 21 at 4:56 PM
4-traders.com logoCollegium Pharmaceutical : Announces Publication of Data on Alternative Modes of Administration of Xtampza ER (NASDAQ:COLL)
www.4-traders.com - September 21 at 8:35 AM
stocksdaily.net logoCollegium Pharmaceutical Inc (NASDAQ:COLL) Ratings in Focus - Stocks Daily (NASDAQ:COLL)
www.stocksdaily.net - September 18 at 4:13 PM
News IconConsensus Analyst Thoughts for: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) , Aldeyra Therapeutics, Inc ... - Wall Street Times (press release) (NASDAQ:COLL)
www.wallstreetnews24.com - September 15 at 9:43 PM
realistinvestor.com logoCollegium Pharmaceutical Inc (NASDAQ:COLL) Is Expected To Post EPS Of $-0.5 - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - September 14 at 8:36 AM
finance.yahoo.com logoCoverage initiated on Collegium Pharmaceutical by Gabelli & Co (NASDAQ:COLL)
finance.yahoo.com - September 14 at 8:36 AM
finance.yahoo.com logoPharmaceutical Industry Leader Ronald M. Burch Joins Relmada Therapeutics Advisory Team (NASDAQ:COLL)
finance.yahoo.com - September 12 at 9:11 AM
News IconSell-side is Weighing in on Collegium Pharmaceutical Inc (NASDAQ:COLL) Earnings - Frisco Fastball (NASDAQ:COLL)
friscofastball.com - September 10 at 8:57 AM
News IconThe Sell-side Consensus is in on Collegium Pharmaceutical Inc ... - National Daily Press (NASDAQ:COLL)
www.nationaldailypress.com - September 9 at 4:11 PM
News IconStudy Says Oxycodone Effectively Manages Chronic Pain in Elderly Patients (NASDAQ:COLL)
www.hcplive.com - September 9 at 9:07 AM
publicnow.com logoReview of Xtampza® ER Published in The Journal of the American Medical Association (NASDAQ:COLL)
www.publicnow.com - September 9 at 9:06 AM
News IconCollegium To Present At The Conference (NASDAQ:COLL)
www.biospace.com - September 8 at 4:11 PM
globenewswire.com logoCollegium Announces the Launch of OpioidIQ Nasdaq:COLL - GlobeNewswire (press release) (NASDAQ:COLL)
globenewswire.com - September 7 at 4:26 PM
finance.yahoo.com logoCollegium to Present at the BioCentury NewsMakers Conference (NASDAQ:COLL)
finance.yahoo.com - September 7 at 4:26 PM
News IconCollegium Pharmaceutical, Inc Clinical Review, Market Share, Strategy, Size and Forecast 2016 - 2020 - Medgadget (blog) (NASDAQ:COLL)
www.medgadget.com - September 6 at 9:11 AM
finance.yahoo.com logoCollegium Announces the Launch of OpioidIQ (NASDAQ:COLL)
finance.yahoo.com - September 6 at 9:11 AM
finance.yahoo.com logoCollegium Announces Scientific Presentations at PAINWeek 2016 Meeting (NASDAQ:COLL)
finance.yahoo.com - September 1 at 11:16 AM
News IconThe 2016 Pharma CI Conference & Exhibition Arrives Soon in New Jersey (NASDAQ:COLL)
www.prlog.org - August 31 at 4:18 PM
News IconShares Down for the Quarter: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Post News (NASDAQ:COLL)
www.kentuckypostnews.com - August 28 at 4:05 PM
News IconStock Tracking Lower for the Quarter: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Post News (NASDAQ:COLL)
www.kentuckypostnews.com - August 21 at 8:55 AM
finance.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Financials (NASDAQ:COLL)
finance.yahoo.com - August 20 at 4:22 PM
News IconInstitutions Have Decreased Their Ownership of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Post News (NASDAQ:COLL)
www.kentuckypostnews.com - August 19 at 11:01 AM
News IconShares Spotted Gapping Up Pre-Bell: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Post News (NASDAQ:COLL)
www.kentuckypostnews.com - August 18 at 9:35 PM
finance.yahoo.com logoEdited Transcript of COLL earnings conference call or presentation 10-Aug-16 8:30pm GMT (NASDAQ:COLL)
finance.yahoo.com - August 18 at 4:21 PM
News IconShares Moving Lower Over the Past Month Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Post News (NASDAQ:COLL)
www.kentuckypostnews.com - August 18 at 10:26 AM
finance.yahoo.com logoTrading Alert: Collegium Pharmaceuticals May See Increased Activity Thursday (NASDAQ:COLL)
finance.yahoo.com - August 17 at 9:46 PM
realistinvestor.com logoAnalysts See Collegium Pharmaceutical Inc (NASDAQ:COLL) Reporting EPS Of $-0.58 - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - August 17 at 4:33 PM
streetinsider.com logoCollegium Pharma (COLL) Announces Publication of Alternative Xtampza ER Administration Modes - StreetInsider.com (NASDAQ:COLL)
www.streetinsider.com - August 16 at 4:24 PM
streetinsider.com logoCollegium Pharma (COLL) Announces Publication of Alternative Xtampza ER Administration Modes (NASDAQ:COLL)
www.streetinsider.com - August 16 at 8:53 AM
finance.yahoo.com logo7:02 am Collegium Pharmaceutical announces the publication of Xtampza study results in the peer-reviewed medical journal, Current Medical Research and Opinion. (NASDAQ:COLL)
finance.yahoo.com - August 16 at 8:52 AM
publicnow.com logoCollegium Announces Publication of Data on Alternative Modes of Administration of Xtampza ER (NASDAQ:COLL)
www.publicnow.com - August 16 at 8:52 AM
fidaily.com logoCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Trading Up – Insiders and Institutional Investors Buying, Short Interest Falling (NASDAQ:COLL)
www.fidaily.com - August 15 at 9:52 PM
fidaily.com logoCollegium Pharmaceutical, Inc. (COLL) Reaches 52-Week Low - Finance Daily (NASDAQ:COLL)
www.fidaily.com - August 12 at 9:34 PM
biz.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 10-Q, Quarterly Report (NASDAQ:COLL)
biz.yahoo.com - August 11 at 10:11 PM
finance.yahoo.com logoCollegium Pharmaceutical posts 2Q loss - Yahoo Finance (NASDAQ:COLL)
finance.yahoo.com - August 11 at 4:29 PM
seekingalpha.com logoCollegium Pharmaceutical's (COLL) CEO Mike Heffernan on Q2 2016 Results - Earnings Call Transcript (NASDAQ:COLL)
seekingalpha.com - August 11 at 10:56 AM
finance.yahoo.com logoBioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up (NASDAQ:COLL)
finance.yahoo.com - August 11 at 10:56 AM
sg.finance.yahoo.com logoCollegium Pharmaceutical posts 2Q loss (NASDAQ:COLL)
sg.finance.yahoo.com - August 10 at 10:33 PM
finance.yahoo.com logoCollegium Reports Second Quarter Financial Results and Provides Corporate Update (NASDAQ:COLL)
finance.yahoo.com - August 10 at 4:24 PM
biz.yahoo.com logoCOLLEGIUM PHARMACEUTICAL, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:COLL)
biz.yahoo.com - August 10 at 4:24 PM
biz.yahoo.com logoCollegium Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:COLL)
biz.yahoo.com - August 10 at 4:24 PM
biz.yahoo.com logoCollegium Pharmaceutical Inc Earnings Call (Q2 2016) (NASDAQ:COLL)
biz.yahoo.com - August 10 at 8:02 AM
biz.yahoo.com logoQ2 2016 Collegium Pharmaceutical Inc Earnings Release - Time Not Supplied (NASDAQ:COLL)
biz.yahoo.com - August 10 at 8:02 AM
News IconFDA Incentivizing Pharma to Develop Less Abusable Pain Medicines (NASDAQ:COLL)
nationalpainreport.com - August 5 at 11:40 AM
publicnow.com logoCollegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update (NASDAQ:COLL)
www.publicnow.com - August 4 at 10:01 PM
News IconCollegium Pharma receives European patent covering Xtampza ER (NASDAQ:COLL)
pharmabiz.com - August 3 at 10:58 AM
streetinsider.com logoCollegium Pharma (COLL) Announces Receipt of European Patent Allowance Covering Xtampza ER - StreetInsider.com (NASDAQ:COLL)
www.streetinsider.com - August 1 at 4:17 PM

Social

Collegium Pharmaceutical (NASDAQ:COLL) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff